Fox Chase Cancer Center News

PHILADELPHIA (November 6, 2015) – A recent preclinical investigation of a novel small molecule called ONC201 suggests it could potentially offer therapeutic benefits for patients diagnosed with either triple negative or non-triple negative breast cancer. Researchers at Fox Chase Cancer Center – Temple Health presented these findings at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from Nov. 5-9, 2015.

PHILADELPHIA (November 5, 2015) – Fox Chase Cancer Center and NBC10 weekend news anchor/reporter Denise Nakano join forces to host Together Facing Lung Cancer, a FREE event designed to provide lung cancer survivors, caregivers, friends, family and healthcare providers to learn more about lung cancer screening and treatment. This event will take place on Thursday, November 19, from 6:00 until 8:00 pm, in the Fox Chase Cafeteria (333 Cottman Avenue in Philadelphia, Pa). Dinner will be served.

PHILADELPHIA (October 20, 2015) – Treatment of early-stage breast cancer with fewer, larger doses of radiation results in equivalent clinical outcomes as conventional radiation therapy, according to new research by Fox Chase Cancer Center – Temple Health investigators. The study revealed no significant difference in survival rates or long-term side effects in patients who received either intense (hypofractionated) radiation therapy over a four-week period or standard radiation therapy over a six- to seven-week period. The eight-year results of the prospective Phase II study were presented October 20 at the 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Antonio, Texas.

PHILADELPHIA (October 19, 2015) – In the biggest study to date evaluating patients with nonmetastatic, large, invasive breast cancers, survival rates were found to be similar for patients treated with either breast conservation surgery and radiation, or mastectomy, according to an analysis published in Cancer.

PHILADELPHIA (October 19, 2015) – Fewer, larger radiation doses did not significantly impact quality-of-life outcomes for prostate cancer patients but may result in potentially worse outcomes for individuals with preexisting urinary problems, according to new research from Fox Chase Cancer Center – Temple Health investigators.

PHILADELPHIA (October 18, 2015) — Men’s health supplements, which are often marketed as having “clinically proven” anti-cancer or healing effects, do not actually provide significant clinical benefits to prostate cancer patients, according to new research by Fox Chase Cancer Center – Temple Health investigators. The first-of-its-kind study reveals that these supplements do not significantly help to prevent distant metastasis, cancer-related death, or adverse effects in prostate cancer patients undergoing radiation therapy. The findings were presented October 18 at the 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Antonio, Texas.

PHILADELPHIA (October 18, 2015) — Prostate cancer is the second most common cancer found in men in the United States, affecting 14 percent, whereas diabetes affects about 9 percent of the population. Even though both conditions are often present in the same individual, it has not been clear how a diabetes diagnosis affects clinical outcomes for prostate cancer. Research at Fox Chase Cancer Center – Temple Health showed that the answer depends on what type of anti-diabetic drugs, if any, prostate cancer patients are taking.

PHILADELPHIA (October 7, 2015) – Fox Chase Cancer Center has partnered with Temple University Athletics to host the 5th Annual Celebration for Survivors. Patients, caregivers, staff, faculty, volunteers and friends will celebrate survivorship by tackling cancer as the undefeated Temple Owls host the University of Central Florida Knights. Past celebrations have included a combination of food tasting, mural making and music.